At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
TAK-227drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Single-dose, Three-way Crossover Evaluation of the Effect of Food on the Pharmacokinetics, Safety, and Tolerability of TAK-227 in Healthy Adult Participants
In Brief
A Phase 1 clinical trial evaluating TAK-227 for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The main aim of this study is to test the effects of food consumption with sponsor compound TAK-227 in healthy participants. The study will also measure side effects, and to check how much TAK-227 stays in the blood over time to work out the best dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedApr 2023
Enrollment StartMay 2023
Primary CompletionJun 2023
Study CompletionJun 2023
TodayJul 2026
First PostedApr 19, 2023
Enrollment StartMay 25, 2023
Primary CompletionJun 19, 2023
Study CompletionJun 26, 2023
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 3.2 years ago
Interventions
TAK-227drug
TAK-227 capsules.